Added to YB: 2026-08-17
Pitch date: 2026-08-13
EVT.DE [neutral]
Evotec SE
-3.09%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.
Market Cap
EUR 612.5M
Pitch Price
EUR 3.56
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.42
P/E
-3.10
EV/Sales
0.87
Sector
Life Sciences Tools and Services
Category
turnaround
Evotec (EVT Germany): Yet another reset
EVT.DE (update): H1 rev -4% to €300.1m, adj EBITDA -€42.7m loss; Q2 worse (rev -10%, EBITDA -€20.8m). Both divisions weak: Discovery -16%, Just-Evotec Biologics -29%. Cut 2026 guide to €570-610m rev (from €700-780m), EBITDA -€70m to -€105m. Horizon targets €75m savings. Recovery timing unclear.
Read full article (2 min)